Bcl-2 expression in 12 B-CLL cultures*
| Time After Onset of Cultures . | Number of Cultures with Higher Bcl-2 Expression After Trx Treatment . | Percentage of Differences in Bcl-2 Expression, Trx vs Control (median values)† . |
|---|---|---|
| Day 1 | 9/12 | +4.5‡ (P = .032)2-153 |
| Day 5 | 10/12 | +7.02-155 (P = .002) |
| Day 12 | 8/12 | +11.52-154 (P = .026) |
| Time After Onset of Cultures . | Number of Cultures with Higher Bcl-2 Expression After Trx Treatment . | Percentage of Differences in Bcl-2 Expression, Trx vs Control (median values)† . |
|---|---|---|
| Day 1 | 9/12 | +4.5‡ (P = .032)2-153 |
| Day 5 | 10/12 | +7.02-155 (P = .002) |
| Day 12 | 8/12 | +11.52-154 (P = .026) |
B-type chronic lymphocytic leukemia (B-CLL) cells were cultured in 1 μg/mL of thioredoxin (Trx) in RPMI 1640, 10% fetal calf serum medium, or as a control in medium only. After 1, 5, or 12 days, cells were stained for Bcl-2 protein and analyzed by FACS. Mean values of three separate FACS experiments (MFI) for each B-CLL were calculated. Each experiment included analysis of 25 000 cells: background isotype MFI was subtracted.
Median value of 12 separate B-CLL cultures. Individual percentage values were on day 1, 5, and 12.
Day 1: +23, +21, +14, +13, +9, +7, +2, +1, +1, −2, −3, −8.
Nonparametrical paired Wilcoxon signed rank sum test shows significant difference between Trx-treated group and control group.
Day 5: +33, +28, +18, +16, +14, +8, +6, +4, +4, +2, −1, −3.
Day 12: +21, +18, +17, +16, +13, +12, +11, +2, −1, −3, −5, −10.